Patents Awarded to AB Biosciences
Lowered affinity antibodies and uses therefor.
Inventor: Hsiu-Ching Chang
Assignee: AB Biosciences, Inc.
Abstract: This patented invention represents a novel antibody technology, offering new approaches for controlled and interpretable biological research. The patent introduces rationally modified antibodies with reduced or eliminated antigen-binding activity. The variable domains of these antibodies have been systematically engineered to lower their affinity without altering the antibody’s native three-dimensional structure. The lowered enables researchers to unambiguously distinguish between effects mediated by specific antigen-antibody interactions and those resulting from non-specific binding, thereby enhancing the accuracy of immunological assays and experimental outcomes.
Human control antibodies and uses therefor.
Inventor: Yen-Ming Hsu, Hsiu-Ching Chang, Jeng-Shin Lee
Assignee: AB Biosciences, Inc.
Abstract: The present invention covers the engineering of CDR-silenced human antibodies through systematic mutations of the antigen-binding regions of both the antibody light chain and heavy chain of the Adalimumab. In addition, the granted patent covers the expression, production, and validation of null antigen binding activity. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.
Lowered affinity antibodies and methods of making the same.
Inventor: Hsiu-Ching Chang
Assignee: AB Biosciences, Inc.
Abstract: The present invention covers a method describing procedures required to generate a CDR-silenced antibody or antibody fragment. The granted claims including methodologies for identifying the antigen-binding amino acid resides within the antibody CDR regions, systematically modification of these residues, generating these variant antibodies in a mammalian expression system, and confirming the loss of the antigen capacity through in vitro and in vivo analyses.
Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use.
Inventor: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang
Assignee: AB Biosciences, Inc.
Abstract: This patent discloses recombinant intravenous immunoglobulin (rIVIG) protein compositions, along with methods for their production, purification, and use. The rIVIG proteins include oligomeric Fc molecules that bind Fc receptors with high avidity and function as potent immunomodulators. Human rIVIG formulations are designed for the treatment of immune-related and autoimmune disorders, as well as for use in transplantation patients. The invention also encompasses non-human rIVIG proteins, including canine-specific formulations for treating autoimmune conditions in dogs, such as autoimmune hemolytic anemia, immune thrombocytopenia purpura, rheumatoid arthritis, and other immune-mediated diseases.
Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use.
Inventor: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang
Assignee: AB Biosciences, Inc.
Abstract: This patent covers nucleic acid compositions from human and non-human sources for producing recombinant intravenous immunoglobulin (rIVIG) proteins. These compositions encode oligomeric Fc molecules that bind Fc receptors with high avidity. The resulting rIVIG proteins serve as immunomodulatory agents for treating autoimmune diseases in humans—such as ITP, CIDP, MS, lupus, and others—and in dogs, including IMHA, ITP, Evans syndrome, and SARDS.